[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Identifieur interne : 000F92 ( Main/Corpus ); précédent : 000F91; suivant : 000F93[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Auteurs : A. Vollaard ; E M Gieling ; P D Van Der Linden ; B. Sinha ; M G J. De BoerSource :
- Nederlands tijdschrift voor geneeskunde [ 1876-8784 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Enzyme Inhibitors (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Antimalarials, Antiviral Agents, Chloroquine, Enzyme Inhibitors, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
On 3 March 2020, the document 'Drug treatment options for patients with COVID-19 (infections with SARS-CoV-2)' was published on the website of the Dutch Working Party on Antibiotic Policy (StichtingWerkgroepAntibioticabeleid, SWAB). Based on a 7-step analysis of the literature, hydroxychloroquine (HCQ) and chloroquine (CQ) were initially included in the SWAB document as possible drug treatments for hospitalised adult COVID-19 patients. However, recent weeks have seen the publication of the results of various studies into the effectiveness of treatment with HCQ and CQ in patients with COVID-19. On the basis of these results, we conclude that there is insufficient evidence to consider HCQ and CQ as meaningful treatment options in patients with COVID-19. Clinically relevant QTc prolongation occurs in at least 1 in 10 COVID-19 patients treated with HCQ or HQ.
PubMed: 32749808
Links to Exploration step
pubmed:32749808Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].</title><author><name sortKey="Vollaard, A" sort="Vollaard, A" uniqKey="Vollaard A" first="A" last="Vollaard">A. Vollaard</name><affiliation><nlm:affiliation>RIVM, Centrum Infectieziektebestrijding, Bilthoven.</nlm:affiliation></affiliation></author><author><name sortKey="Gieling, E M" sort="Gieling, E M" uniqKey="Gieling E" first="E M" last="Gieling">E M Gieling</name><affiliation><nlm:affiliation>UMC Utrecht, afd. Klinische Farmacie, Utrecht.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Contact: E.M. Gieling (e.m.gieling@umcutrecht.nl).</nlm:affiliation></affiliation></author><author><name sortKey="Van Der Linden, P D" sort="Van Der Linden, P D" uniqKey="Van Der Linden P" first="P D" last="Van Der Linden">P D Van Der Linden</name><affiliation><nlm:affiliation>Tergooi, afd. Klinische Farmacie, Hilversum.</nlm:affiliation></affiliation></author><author><name sortKey="Sinha, B" sort="Sinha, B" uniqKey="Sinha B" first="B" last="Sinha">B. Sinha</name><affiliation><nlm:affiliation>UMCG, afd. Medische Microbiologie & Infectiepreventie, Groningen.</nlm:affiliation></affiliation></author><author><name sortKey="De Boer, M G J" sort="De Boer, M G J" uniqKey="De Boer M" first="M G J" last="De Boer">M G J. De Boer</name><affiliation><nlm:affiliation>LUMC, afd. Infectieziekten, Leiden.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32749808</idno><idno type="pmid">32749808</idno><idno type="wicri:Area/Main/Corpus">000F92</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].</title><author><name sortKey="Vollaard, A" sort="Vollaard, A" uniqKey="Vollaard A" first="A" last="Vollaard">A. Vollaard</name><affiliation><nlm:affiliation>RIVM, Centrum Infectieziektebestrijding, Bilthoven.</nlm:affiliation></affiliation></author><author><name sortKey="Gieling, E M" sort="Gieling, E M" uniqKey="Gieling E" first="E M" last="Gieling">E M Gieling</name><affiliation><nlm:affiliation>UMC Utrecht, afd. Klinische Farmacie, Utrecht.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Contact: E.M. Gieling (e.m.gieling@umcutrecht.nl).</nlm:affiliation></affiliation></author><author><name sortKey="Van Der Linden, P D" sort="Van Der Linden, P D" uniqKey="Van Der Linden P" first="P D" last="Van Der Linden">P D Van Der Linden</name><affiliation><nlm:affiliation>Tergooi, afd. Klinische Farmacie, Hilversum.</nlm:affiliation></affiliation></author><author><name sortKey="Sinha, B" sort="Sinha, B" uniqKey="Sinha B" first="B" last="Sinha">B. Sinha</name><affiliation><nlm:affiliation>UMCG, afd. Medische Microbiologie & Infectiepreventie, Groningen.</nlm:affiliation></affiliation></author><author><name sortKey="De Boer, M G J" sort="De Boer, M G J" uniqKey="De Boer M" first="M G J" last="De Boer">M G J. De Boer</name><affiliation><nlm:affiliation>LUMC, afd. Infectieziekten, Leiden.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Nederlands tijdschrift voor geneeskunde</title><idno type="eISSN">1876-8784</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Antimalarials (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chloroquine (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term><term>Antiviral Agents</term><term>Chloroquine</term><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">On 3 March 2020, the document 'Drug treatment options for patients with COVID-19 (infections with SARS-CoV-2)' was published on the website of the Dutch Working Party on Antibiotic Policy (StichtingWerkgroepAntibioticabeleid, SWAB). Based on a 7-step analysis of the literature, hydroxychloroquine (HCQ) and chloroquine (CQ) were initially included in the SWAB document as possible drug treatments for hospitalised adult COVID-19 patients. However, recent weeks have seen the publication of the results of various studies into the effectiveness of treatment with HCQ and CQ in patients with COVID-19. On the basis of these results, we conclude that there is insufficient evidence to consider HCQ and CQ as meaningful treatment options in patients with COVID-19. Clinically relevant QTc prolongation occurs in at least 1 in 10 COVID-19 patients treated with HCQ or HQ.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32749808</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1876-8784</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><PubDate><Year>2020</Year><Month>06</Month><Day>02</Day></PubDate></JournalIssue><Title>Nederlands tijdschrift voor geneeskunde</Title><ISOAbbreviation>Ned Tijdschr Geneeskd</ISOAbbreviation></Journal><ArticleTitle>[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">D5141</ELocationID><Abstract><AbstractText>On 3 March 2020, the document 'Drug treatment options for patients with COVID-19 (infections with SARS-CoV-2)' was published on the website of the Dutch Working Party on Antibiotic Policy (StichtingWerkgroepAntibioticabeleid, SWAB). Based on a 7-step analysis of the literature, hydroxychloroquine (HCQ) and chloroquine (CQ) were initially included in the SWAB document as possible drug treatments for hospitalised adult COVID-19 patients. However, recent weeks have seen the publication of the results of various studies into the effectiveness of treatment with HCQ and CQ in patients with COVID-19. On the basis of these results, we conclude that there is insufficient evidence to consider HCQ and CQ as meaningful treatment options in patients with COVID-19. Clinically relevant QTc prolongation occurs in at least 1 in 10 COVID-19 patients treated with HCQ or HQ.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vollaard</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>RIVM, Centrum Infectieziektebestrijding, Bilthoven.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gieling</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>UMC Utrecht, afd. Klinische Farmacie, Utrecht.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Contact: E.M. Gieling (e.m.gieling@umcutrecht.nl).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Linden</LastName><ForeName>P D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Tergooi, afd. Klinische Farmacie, Hilversum.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>UMCG, afd. Medische Microbiologie & Infectiepreventie, Groningen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>M G J</ForeName><Initials>MGJ</Initials><AffiliationInfo><Affiliation>LUMC, afd. Infectieziekten, Leiden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Hydroxychloroquine en chloroquine bij COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ned Tijdschr Geneeskd</MedlineTA><NlmUniqueID>0400770</NlmUniqueID><ISSNLinking>0028-2162</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32749808</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32749808
|texte= [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32749808" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |